The findings showed that discontinuing everolimus was linked to a higher incidence of DNMs. Nationwide Analysis Suggested Lower Cancer IncidenceResearchers analysed 7,981 adults who underwent liver transplantation for cirrhosis or hepatocellular carcinoma between 2009 and 2020, with hepatocellular carcinoma accounting for 44% of transplants. Patients who initiated everolimus had a lower incidence of DNMs (HR 0.84; 95% CI 0.79-0.88). Implications for Clinical PracticeAlthough sustained everolimus exposure was linked to a lower incidence of DNMs, this did not translate into improved 10-year overall survival. Everolimus and de novo malignancies after liver transplantation: a nationwide emulated trial using real-world data.